Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph node transfer for the treatment of patients with secondary lymphedema associated with the treatment of breast cancer

Next Previous
X
Search
Trial Profile

A Phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph node transfer for the treatment of patients with secondary lymphedema associated with the treatment of breast cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AdVEGF-Herantis (Primary)
  • Indications Lymphoedema
  • Focus Therapeutic Use
  • Acronyms AdeLE
  • Sponsors Herantis Pharma

    • Most Recent Events

    • 18 Oct 2023 Planned End Date changed from 7 Mar 2022 to 31 Dec 2024.
    • 01 Nov 2022 Results published in the Journal of Plastic, Reconstructive and Aesthetic Surgery: JPRAS
    • 16 Dec 2019 According to an Herantis Pharma media release , the company expects to unblind the study and announce its top-line results in the first quarter of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top